In osteosarcoma cells, RhoA was shown to activate the p42/p44 MAPKs/Bcl-2 survival pathway, which may be inhibited by lipophilic statins, inducing caspase-dependent apoptosis [122]. Here, RHOA is linked to osteosarcoma.